Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Sodium thiosulfate - Fennec Pharmaceuticals

Next Previous
Drug Profile

Sodium thiosulfate - Fennec Pharmaceuticals

Alternative Names: PEDMARK; PEDMARQSI; Sodium hyposulfite; STS - Fennec

Latest Information Update: 22 Mar 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Oregon Health & Science University
  • Developer Fennec Pharmaceuticals
  • Class Antidotes; Antituberculars; Chemoprotectants; Thiosulfates; Vasodilators
  • Mechanism of Action Antioxidants; Chelating agents
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Sensorineural hearing loss
  • New Molecular Entity No

Highest Development Phases

  • Marketed Sensorineural hearing loss

Most Recent Events

  • 18 Mar 2024 Sodium thiosulfate licensed to Norgine for commercialization in Europe, Australia, and New Zealand
  • 31 Dec 2023 Fennec Pharmaceuticals has patent protection for Sodium thiosulfate in Indonesia
  • 31 Oct 2023 Registered for Sensorineural hearing loss (In adolescents, In children, In infants, Prevention, Chemotherapy-induced) in United Kingdom (IV)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top